GlassScriptPhysician profile
Habib H Doss
NPI 1174565543
$19,424.96
in general payments reported to CMS, 2019-2025
70 companies · $2,971 in 2025
The $2,971 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,930 · 2020: $6,122 · 2021: $34.93 · 2022: $2,128 · 2023: $1,900 · 2024: $2,338 · 2025: $2,971.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,889 · Education: $321.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,888.99 |
| Education | $320.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $2,044.73 | 2020-2025 | Xpovio |
| Janssen Biotech, INC. | $1,543.49 | 2019-2025 | Darzalex, Imbruvica, Tecvayli |
| Beigene USA, INC. | $1,415.60 | 2020-2025 | Tevimbra, Brukinsa |
| Aveo Pharmaceuticals, INC. | $1,384.87 | 2022-2025 | Fotivda |
| Rigel Pharmaceuticals, INC. | $1,379.55 | 2019-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Novartis Pharmaceuticals Corporation | $1,076.46 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $902.54 | 2019-2025 | Keytruda, Welireg, Keytruda Qlex |
| Astrazeneca Pharmaceuticals LP | $706.34 | 2019-2025 | Tagrisso, Calquence, Imfinzi |
| Eli Lilly and Company | $500.00 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $492.14 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Amgen INC. | $448.54 | 2019-2023 | Lumakras, Blincyto, Kyprolis |
| Celgene Corporation | $431.27 | 2019-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $358.08 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| Seagen INC. | $345.13 | 2019-2023 | Padcev, Tukysa |
| Astellas Pharma US INC | $335.75 | 2019-2025 | Xospata, Padcev, Xtandi |
Show all 70 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $330.24 | 2022-2025 | Venclexta |
| Genentech USA, INC. | $329.92 | 2019-2025 | Venclexta, Tecentriq |
| Eisai INC. | $314.63 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $299.09 | 2019-2025 | Libtayo |
| Pfizer INC. | $278.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $264.03 | 2019-2025 | |
| Genzyme Corporation | $252.27 | 2019-2025 | |
| Incyte Corporation | $229.80 | 2019-2025 | Pemazyre, Monjuvi, Zynyz |
| Takeda Pharmaceuticals U.S.A., INC. | $211.45 | 2019-2025 | Ninlaro, Iclusig |
| Exelixis INC. | $206.55 | 2019-2025 | Cabometyx |
| Kite Pharma, INC. | $205.27 | 2020-2025 | Yescarta |
| Pharmacyclics LLC, An Abbvie Company | $183.98 | 2019-2023 | Imbruvica, Epkinly |
| Pharmaessentia USA Corporation | $176.56 | 2023-2025 | Besremi |
| Glaxosmithkline, LLC. | $173.36 | 2020-2025 | Ojjaara, Zejula, Jemperli |
| Gilead Sciences, INC. | $167.52 | 2019-2024 | Trodelvy |
| Taiho Oncology, INC. | $166.62 | 2019-2025 | |
| Array Biopharma INC | $156.42 | 2019-2023 | Mektovi, Braftovi, Paxlovid |
| Alexion Pharmaceuticals, INC. | $143.53 | 2019-2025 | Ultomiris |
| Stemline Therapeutics INC. | $134.82 | 2023-2025 | Orserdu |
| Lilly USA, LLC | $119.45 | 2019-2023 | Jaypirca, Retevmo, Verzenio |
| Emd Serono, INC. | $115.11 | 2019-2025 | Tepmetko, Bavencio |
| Jazz Pharmaceuticals INC. | $108.70 | 2023-2025 | |
| Sanofi-Aventis U.S. LLC | $99.95 | 2019 | |
| Tesaro, INC. | $97.87 | 2019 | |
| Tersera Therapeutics LLC | $87.77 | 2023-2025 | Zoladex, Xermelo |
| Blueprint Medicines Corporation | $71.47 | 2020-2025 | Ayvakit |
| G1 Therapeutics, INC. | $69.65 | 2022-2023 | Cosela |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.69 | 2019-2024 | Gilotrif |
| Puma Biotechnology, INC. | $66.30 | 2019-2024 | |
| Teva Pharmaceuticals USA, INC. | $63.68 | 2019 | |
| Biocompatibles, INC. | $63.10 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $62.71 | 2019-2025 | Onivyde |
| Adc Therapeutics America, INC. | $57.65 | 2023-2024 | |
| Verastem, INC. | $57.16 | 2019-2020 | |
| Sumitomo Pharma America, INC. | $54.27 | 2024-2025 | Orgovyx |
| Mirati Therapeutics, INC. | $51.85 | 2023 | Krazati |
| Dendreon Pharmaceuticals LLC | $47.77 | 2024-2025 | Provenge |
| Servier Pharmaceuticals LLC | $45.99 | 2024-2025 | |
| Genmab U.S., INC. | $45.62 | 2024-2025 | Epkinly |
| Dova Pharmaceuticals | $39.86 | 2019 | |
| Sobi, INC | $38.26 | 2024-2025 | |
| Cti Biopharma Corp. | $34.00 | 2023 | Vonjo |
| Fennec Pharmaceuticals, INC. | $31.58 | 2025 | Fyarro |
| Mylan Institutional INC. | $29.45 | 2019-2020 | |
| Deciphera Pharmaceuticals INC. | $26.90 | 2024 | Qinlock |
| Beone Medicines USA, INC. | $23.65 | 2025 | Tevimbra |
| Sun Pharmaceutical Industries INC. | $23.25 | 2024 | |
| Verity Pharmaceuticals INC. | $22.96 | 2024 | Trelstar |
| Morphosys, US INC. | $21.02 | 2023 | Monjuvi |
| Recordati_rare_diseases_inc. | $19.81 | 2025 | Sylvant |
| Pharmacosmos Therapeutics INC. | $19.50 | 2024 | Cosela |
| Lexicon Pharmaceuticals, INC. | $15.64 | 2020 | |
| Partner Therapeutics, INC. | $14.64 | 2019 | |
| Amag Pharmaceuticals, INC. | $11.50 | 2019 | |
| Eusa Pharma (US) LLC | $11.41 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Habib Doss listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.